This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Lupin Appoints Dr. Maurice Chagnaud As President-Europe & Head Of Inhalation Strategy

MUMBAI, India and BALTIMORE, February 18, 2014 /PRNewswire/ --

Pharma major Lupin, today announced the appointment of Dr. Maurice Chagnaud as its President, Europe and Head of Inhalation Strategy. He will be based at Schaffhausen, Switzerland. Dr. Chagnaud has over 20 years of experience in Pharmaceutical business in Europe having worked with Teva and Merck Generics.  He joins Lupin from Israeli drug major, Teva, where he was the Senior Vice President, Central & Eastern Europe, responsible for revenues in excess of over 1 Billion Euros.

In his new role at Lupin, Dr. Chagnaud will assume full responsibility for the Company's European business including the company strategy for Generics & Specialty business in Western and CEE region including Russia & CIS countries. He will also be responsible for developing Lupin's core strategy for Inhalation in the developed markets.

Commenting on the appointment, Vinita Gupta, Chief Executive Officer, Lupin Limited said, " Over the years, Lupin has recorded consistent growth across advanced markets like the  US  and  Japan . With Maurice ' s rich experience we look forward to building our business in  Europe ,  in particular around Complex generics & Specialty.  We are delighted to welcome him into the Lupin family. "

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community


Chart of I:DJI
DOW 16,588.96 -65.81 -0.40%
S&P 500 1,985.34 -2.32 -0.12%
NASDAQ 4,819.9880 +7.28 0.15%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs